Home > Resources > Whitepapers > Healthcare system readiness for the adoption of advanced therapies: learnings from the introduction of CAR T cell therapies in the UK

Cell and Gene Therapy

Healthcare system readiness for the adoption of advanced therapies: learnings from the introduction of CAR T cell therapies in the UK

September 17, 2021

The adoption of CAR T therapies in the UK NHS is a success story, especially seen in
relation to the experience in many other countries. The UK NHS showed itself to be agile,
and responsive to addressing the unique challenges these therapies present, which
facilitated access to patients earlier than in many other countries. (including delivery centre
selection, development of service specifications, collaboration with manufacturers
throughout the preparation phase for adoption, establishment of national multidisciplinary
CAR T team to ensure equity of access and prioritization of resources (where needed)).

Spotlight

Caribou Biosciences

Caribou Biosciences is a leading biotechnology company in genome engineering. We develop technology-based solutions for cellular engineering and analysis based on the CRISPR-Cas9 technology platform.

OTHER WHITEPAPERS

Microfluidics: Big developments on thesmall scale

whitePaper | February 23, 2023

Life sciences is a blanket term used to describe the study of all things relative to living organisms, such as biology, physiology, and biochemistry.

Becoming a life sciences superpower

whitePaper | September 1, 2021

This report advocates for increased, long-term public investment in research and innovation, particularly in the life sciences sector, to accelerate the UK on its trajectory as a global leader in the field. This report sets out recommendations ahead of the Comprehensive Spending Review for policymakers to support innovative businesses, achieve the Prime Minister’s aim of becoming a life sciences superpower, and ultimately, deliver health benefits for Britain – and the world – for generations to come.

Cell and Gene Therapy Hot Buttons Series

whitePaper | September 27, 2022

Cell and Gene Therapy (CAGT) activity has increased dramatically in recent decades, especially in Chimeric Antigen Receptor T-Cell (CAR-T) clinical trials and therapy registrations. The IQVIA CAGT Hot Buttons series covers basic concepts in CAGT for newcomers to this field.

Transforming cell & gene therapy manufacturing

whitePaper | February 25, 2022

Digitalization and automation promise a better way to streamline the transfer of cell and gene therapies from drug discovery – to commercial production.

BIOTECHNOLOGY INNOVATION ORGANIZATION

whitePaper | January 4, 2022

The Biotechnology Innovation Organization (BIO) appreciates the opportunity to participate in the 2022 Special 301 Review: Identification of Countries under Section 182 of the Trade Act of 1974: Request for Public Comment and Announcement of Public Hearing.

Impurity profiling and analysis of TheraPure GMP nucleotides

whitePaper | March 22, 2023

Nucleoside triphosphates (NTPs) are key building blocks of many nucleic acid therapeutics and vaccines. These molecules are a vital component of revolutionary new medicines.